Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB announced preliminary results from its phase 2 TRIFOUR trial, evaluating nadunolimab in combination with chemotherapy for advanced triple-negative breast cancer (TNBC). The study showed similar overall response rates between the nadunolimab group and the reference chemotherapy group, with acceptable tolerability. The findings highlight the challenges in treating TNBC and the ongoing need for new therapeutic options. Further analyses, including overall survival data, are awaited to determine the full impact of nadunolimab in this setting.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based therapies for cancer treatment. Their primary product, nadunolimab, is an IL1RAP antibody being tested in various cancer indications, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
Average Trading Volume: 3,185,483
Current Market Cap: SEK999.4M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.